Categories Earnings, Health Care

CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot

— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share

— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected

— Net loss before recognition of the deemed dividends was $5.3 million

— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018

— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin

— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Lyft (LYFT) expects average ride volumes to improve through Q1 2021

Shares of Lyft Inc. (NASDAQ: LYFT) were up 8% in afternoon hours on Wednesday. The stock has gained 53% over the past 12 months and 25% since the beginning of

With new strategy in place, Target looks poised to tap growing online demand

Department store chain Target Corp. (NYSE: TGT), which has been thriving on the pandemic-driven shopping boom since early last year, maintained its strong performance during the holiday season and entered

Infographic: Dollar Tree’s (DLTR) performance in Q4

Dollar Tree (NYSE: DLTR) reported fourth-quarter financial results before the opening bell on Wednesday. The discount store reported a 7% increase in Q4 net sales to $6.7 billion. The company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top